For instance, in gastric cancer, VEGF upregulation promotes chemoresistance to oxaliplatin via enhanced angiogenesis [9], whereas in hepatocellular carcinoma, VEGF downregulation improves sensitivity to sorafenib [10]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.